RxDoctor Payments Data

Sophia Drinis, MD

Urology · Beverly, MANPI 1932175924

Payments from drug & device makers

$5,697in general payments, 2019–2025

Across 128 payments — averaging $44.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$4K
  • Astellas Pharma US Inc$330
  • Boston Scientific$220
  • Pfizer$205
  • Medtronic$98
  • Axonics, Inc.$91
  • plus $446 from 14 others

What the payments were for

  • Travel & lodging$3,05854%
  • Food & beverage$2,13437%
  • Education$5049%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast54$4,306
Astellas Pharma US Inc22$330
Boston Scientific6$220
Pfizer9$205
Medtronic(2 entities)5$98
Axonics, Inc.4$91
Endo Pharmaceuticals Inc.6$87
Urovant Sciences Inc3$63
Neotract Inc.2$53
AbbVie2$41
Myriad Genetic Laboratories, Inc.2$36
Bayer2$35
Zyla Life Sciences, Inc.2$28
Laborie Medical Technologies Corp.1$25
Johnson & Johnson1$19
Antares Pharma, Inc.1$17
Therapeuticsmd, Inc.1$14
ABC Home Medical Supply, Inc.1$14
Myovant Sciences Inc.1$14
Innovative Medical Technologies, LLC3$0

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,697 in reported general payments places this provider in the 70th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$175,420
Medicare patients
358
Services billed
3,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol222$14,284
GemtesaVibegron17$12,912
MyrbetriqMirabegron20$9,824
Oxybutynin Chloride ErOxybutynin Chloride128$4,079
Tamsulosin Hcl153$2,469
Methenamine Hippurate42$2,168
Tolterodine Tartrate ErTolterodine Tartrate24$1,827
Trospium Chloride27$1,576
Trimethoprim17$1,246
Finasteride49$1,173
Alfuzosin Hcl ErAlfuzosin Hcl14$404
Cefdinir23$266
Ciprofloxacin Hcl74$248
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim44$112
Cephalexin33$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$330$9,82420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 327 urology providers in Massachusetts.

Other urology in Beverly

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →